Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial
- Thursday, May 12, 2022, 7:20
- PR Newswire
- Add a comment
WIXOM, Mich., May 12, 2022 /PRNewswire/ — Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it provided the U.S. Food and Drug Administration (FDA) with the…